PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME) (MATISSE)

• Safety and dose-limiting toxicities (Stratum I) [ Time Frame: 6 months post-injection ]
  - To determine the safety and dose-limiting toxicities of a single intravitreal (IVT) injection of PF-04523655 in subjects with low vision
• Pharmacokinetics (Stratum I) [ Time Frame: 6 months post-injection ]
  - To determine the pharmacokinetics (PK) of a single IVT injection of PF-04523655 in subjects with low vision
• Safety and tolerability (Stratum II) [ Time Frame: 30 days after the last injection ]
  - To evaluate the safety and tolerability of PF-04523655 alone and in combination with ranibizumab in subjects with diabetic macular edema (DME)
• Efficacy (Stratum II) [ Time Frame: 30 days after the last injection ]
  - To evaluate the ability of PF-04523655 alone and in combination with ranibizumab to improve visual acuity compared to ranibizumab alone in subjects with DME

Patients will be enrolled concurrently according to one of two sets of criteria designated as Stratum I and Stratum II.

1. Stratum I will enroll up to 24 subjects with low vision, inclusive of possible intermediate doses, in up to 4 cohorts of 3-6 evaluable subjects.
2. Stratum II will enroll approximately 240 subjects with DME 1:1:1:1 in up to 4 cohorts of 60 evaluable subjects.

• Choroidal Neovascularization
• Diabetic Retinopathy
• Diabetic Macular Edema

• Drug: PF-04523655 (Stratum I)
  PF-04523655 (a small interfering RNA) - a single IVT injection
  Other Name: PF-655
• Drug: ranibizumab
  6 monthly IVT injections of ranibizumab (Stratum II)
  Other Name: Lucentis
• Drug: PF-04523655 (Stratum II)
  6 monthly IVT injections of PF-04523655 (a small interfering RNA)
  Other Name: PF-655

• Experimental: PF-04523655 (Stratum II)
  Stratum II, 6 monthly injections of PF-04523655 only
  Intervention: Drug: PF-04523655 (Stratum II)
• Experimental: PF-04523655 and ranibizumab
  Stratum II, 6 monthly injections of PF-0423655 and ranibizumab administered in combination
  Interventions:

  • Drug: ranibizumab
  • Drug: PF-04523655 (Stratum II)
• Active Comparator: ranibizumab
  Stratum II, 6 monthly IVT injections of ranibizumab only
  Intervention: Drug: ranibizumab
• Experimental: PF-04523655 (Stratum I)
  Stratum I
  Intervention: Drug: PF-04523655 (Stratum I)

Key Stratum I Inclusion Criteria:

1. Visual acuity in the study eye ≤ 20/200.
2. Low visual acuity is the result of an irreversible condition affecting the posterior segment of the study eye.

Key Stratum I Exclusion Criteria:

1. History of vitrectomy.
2. History of IVT injection in study eye within last 6 months.
3. History of vitreous hemorrhage, retinal detachment, or invasive trauma in study eye.
4. History of uveitis or endophthalmitis in either eye.
5. Any active inflammatory condition in study eye.
6. Received any drugs known to cause optic nerve or retinal toxicity within 14 days prior to dosing.
7. Any medical condition, concomitant therapy or previous incisional or laser surgery that, in the opinion of the Investigator, would preclude IVT injection in the study eye.
8. Intraocular pressure in either eye ≥25 mmHg on maximal medication.
9. Cataract surgery and laser corneal surgery within 3 months prior to dosing in the study eye and all other intraocular surgeries at any time.
10. Participation in a concurrent interventional study within 30 days prior to dosing.

Key Stratum II Inclusion Criteria:

1. History of diabetes mellitus (Type 1 or Type 2).
2. Retinal thickening secondary to the edema caused by diabetes mellitus.
3. Best corrected visual acuity (BCVA) of 20/40 or worse and up to 20/320 or better in the study eye at Screening.
4. Standard of care treatment for DME can be withheld for at least 90 days after the subject has enrolled in the study (study eye only).

Key Stratum II Exclusion Criteria:

1. History of panretinal photocoagulation within 6 months or macular laser photocoagulation within 3 months of prior to dosing in the study eye.
2. Any IVT injection therapy performed in the study eye within 3 months prior to dosing.
3. Iris neovascularization, vitreous hemorrhage, tractional retinal detachment, vitreomacular traction, clinically significant epiretinal membrane or clinically significant preretinal fibrosis involving the macula in the study eye.
4. History of vitreoretinal surgery or incisional glaucoma surgery in the study eye.
5. Prior intraocular surgery or corneal laser surgery, performed within 3 months prior to dosing in the study eye.
6. Received any drugs known to cause optic nerve or retinal toxicity within 14 days prior to dosing.
7. High risk (in the opinion of the Investigator) proliferative diabetic retinopathy (PDR) in the study eye.
8. Current infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye.
9. Monocular subjects.
10. History of idiopathic or autoimmune uveitis in either eye.
11. Aphakia or absence of the posterior capsule in the study eye.
12. Structural damage to the center of the macula in the study eye likely to preclude improvement in visual acuity following the resolution of macular edema.
13. Uncontrolled glaucoma in either eye.
14. Spherical equivalent of the refractive error in the study eye of more than -8 diopters myopia.
15. Use of corticosteroids that, in the Investigator's opinion, may change the status of the subject's diabetic retinopathy in the study eye.